Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Despite amisulpride recording millions of annual prescriptions abroad with established safety, the FDA barred LB Pharmaceuticals from submitting foreign clinical data. The agency treats the modified drug as completely new, forcing developers to run a full domestic development program from scratch rather than relying on existing evidence.

Related Insights

Transitioning an oral therapy into a once-monthly injectable requires launching a completely separate clinical development program. Despite prior oral trials, the FDA requires full Phase 3 studies to independently establish safety and efficacy for the alternate formulation, resetting the regulatory timeline.

A treaty between the FDA and Brazil's health department allows clinical trials conducted in Brazil to be accepted by the FDA. This provides a pathway for biotech startups to drastically reduce R&D costs and accelerate timelines without compromising the "gold standard" of US regulatory approval.

The FDA initially agreed uniQure could use the robust Enroll HD database for its control group, a standard practice for rare diseases. Their later reversal, demanding a new placebo trial, creates significant regulatory uncertainty, making it harder for companies to develop therapies for rare conditions.

The FDA retreated from its initial plan to impose a $10M penalty on companies conducting initial trials abroad. The new proposal, a modest $2M fee reduction for domestic trials, is considered too small to change corporate strategy, effectively making the policy a symbolic gesture rather than a meaningful incentive.

The FDA's request for a new Phase 3 trial from Miram, despite strong pivotal data, highlights a growing unpredictability. This decision contradicts the recent approval of a competitor's drug with weaker data, signaling a puzzling and conservative shift that experts didn't anticipate.

Moving first-in-human studies to countries like Australia and China is now a core business strategy, not just a cost-saving measure. It allows U.S. biotechs to navigate a more flexible regulatory environment and accelerate development timelines.

The FDA is requiring higher US patient enrollment in global trials to address concerns that results from predominantly non-US populations (e.g., Asia) may not be generalizable. This reflects worries about differences in prior standard-of-care treatments and potential pharmacogenomic variations affecting outcomes.

Amidst growing uncertainty at the US FDA, biotech companies are using a specific de-risking strategy: conducting early-stage clinical trials in countries like South Korea and Australia. This global approach is not just about cost but a deliberate move to get fast, reliable early clinical data to offset domestic regulatory instability and gain a strategic advantage.

Despite targeting the same orphan indication for kidney transplants, Hansa Biopharma had to conduct completely separate clinical trials for Europe and the US. This highlights how differing regulatory demands from the FDA (requiring a control arm) and EMA can significantly increase costs and complexity for global biotech companies.

With over 2.2 million patients already treated in Japan, Crystallis successfully argued for a smaller, non-replicated Phase 3 trial program with the FDA. The agency acknowledged the vast Asian safety database, allowing for a more capital-efficient path to U.S. approval for their drug, detenuride.